06-19 Ensol Biosciences Inc. announced that it has received KRW 4.99999554 billion in funding from Smart & Growth Co., Ltd. CI
06-04 Ensol Biosciences Inc. announced that it expects to receive KRW 4.99999554 billion in funding from Smart & Growth Co., Ltd. CI
31/07/25 Ensol Biosciences Inc. announced that it has received KRW 1.99999305 billion in funding from Capstone Partners Co., Ltd. CI
22/07/25 Ensol Biosciences Inc. announced that it expects to receive KRW 1.99999305 billion in funding from Capstone Partners Co., Ltd. CI
18/07/25 Ensol Biosciences Inc. announced that it has received KRW 20.438726 billion in funding CI
10/07/25 Ensol Biosciences Inc. announced that it expects to receive KRW 20.438726 billion in funding CI
11/06/25 Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. for KRW 14.2 billion. CI
24/01/25 Ensol Biosciences Inc. announced that it has received KRW 9.99999539 billion in funding CI
12/12/24 Ensol Biosciences Inc. announced that it expects to receive KRW 9.99999539 billion in funding CI
14/11/24 Ensol Biosciences Inc. announced that it has received KRW 1.5 billion in funding from Samho Green Investment, Inc. CI
06/11/24 Ensol Biosciences Inc. announced that it expects to receive KRW 1.5 billion in funding from Samho Green Investment, Inc. CI
20/09/24 Ensol Biosciences Inc. announced that it has received KRW 1 billion in funding from MAGNA Investment Co., Ltd. CI
09/09/24 Ensol Biosciences Inc. announced a financing transaction CI
1 day+1.24%
1 week+1.63%
Current month+6.33%
1 month-13.34%
3 months-19.16%
6 months-29.91%
Current year-19.35%
1 week 10,200
Extreme 10200
10,900
1 month 8,810
Extreme 8810
12,490
Current year 8,810
Extreme 8810
17,900
1 year 8,810
Extreme 8810
17,900
3 years 2,800
Extreme 2800
38,800
5 years 2,800
Extreme 2800
38,800
10 years 2,800
Extreme 2800
38,800
Manager TitleAgeSince
Chief Executive Officer 66 20/02/2001
Corporate Officer/Principal 54 28/03/2024
Corporate Officer/Principal 61 27/03/2020
Director TitleAgeSince
Director/Board Member 72 17/07/2022
Director/Board Member 66 17/01/2022
Director/Board Member 66 20/02/2001
Date Insider Type Main position Quantity % Market Cap.
02/10/25 Buy 3,100 0.0253%
02/10/25 Buy 25,000 0.2041%
02/10/25 Buy 5,500 0.0449%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+1.63%-39.45%-7.83% 100M
+3.78%+5.37%+47.06%-0.42% 80.91B
+5.49%+20.35%-38.64%-38.47% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-3.71%+11.44%+170.56% 47.97B
+4.24%+6.08%+59.56%-16.41% 31.41B
+176.97%+173.88%+524.79%+56.99% 25.14B
+4.05%+6.38%+50.33%+98.01% 25.03B
+1.66%+2.83%-3.58%+212.40% 21.45B
+0.22%+5.48%+65.69%+127.79% 16.93B
Average +19.59%+2.91%+67.49%+63.29% 35.27B
Weighted average by Cap. +14.82%+3.07%+55.35%+50.16%
Logo Ensol Biosciences Inc.
Ensol Biosciences Inc is a Korea-based company primarily engaged in the research and development of pharmaceuticals. The Company is engaged in the research and development of 'Peniel2000' (P2K) for degenerative disc disease, 'P2K' indication expansion, 'Engedi1000' (E1K) for knee osteoarthritis, and anticancer combination therapy. The Company is also engaged in the research and development of canine osteoarthritis therapy, 'Moriah1000' (M1K) for alzheimer’s disease (AD), and 'Hadassah1000' (H1K) for oral obesity treatment. In addition, the Company is engaged in the provision of services such as synthesis and purification services, and consulting on of breeding information systems.
Employees
-
Date Price Change Volume
19/08/26 10,590.00 +1.24% 1,242
18/08/26 ₩10,460.00 -2.97% 5,425
14/08/26 ₩10,780.00 +0.94% 4,124
13/08/26 ₩10,680.00 +1.91% 4,971
12/08/26 ₩10,480.00 +0.58% 4,418
  1. Stock Market
  2. Stocks
  3. A140610 Stock